A team of researchers at the IRCM, led by André Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.
“Our team is studying how natural killer cells can eliminate abnormal hematopoietic (blood) cells,” explains Dr. Veillette, Director of the Molecular Oncology research unit at the IRCM. “NK (natural killer) cells are crucial to the immune system and play a critical role in protecting us against viruses and cancer cells.”
In a previous study, the IRCM researchers found the SAP molecule to be an essential component of NK cells’ ability to kill abnormal blood cells, which can be found in blood cancers such as leukemia and lymphoma, as well as in certain infectious viral diseases like infectious mononucleosis.
“In addition to SAP, a protein called EAT-2 can also be found in NK cells,” adds Dr. Veillette. “We knew that EAT-2 cooperates with SAP, and, with this research project, we wanted to better understand why they are both required for the proper functioning of NK cells.”
Using a variety of genetic, biochemical and imaging approaches, the researchers successfully defined the molecular and cellular mechanisms by which EAT-2 controls the activation of NK cells.
“We identified the molecular chain of events that occur, and showed that EAT-2 and SAP perform different functions using distinct mechanisms,” says Dr. Veillette. “These findings explain the cooperative and essential function of these two molecules in activating NK cells, thereby allowing them to kill abnormal blood cells.”
“EAT-2 and SAP are molecules found inside NK cells, and they are linked to receptors of the SLAM family on the cell surface,” concludes Dr. Veillette. “Because they can make better drug targets, our future work will focus on these receptors, which could eventually lead to identifying new potential treatment avenues for blood cancers such as leukemia and lymphoma.”
According to the Leukemia & Lymphoma Society of Canada, one person in Canada is diagnosed with a blood cancer approximately every 28 minutes. In 2013, leukemia, lymphoma, myeloma and myelodysplastic syndromes caused an estimated 6,850 deaths in the country. Leukemia and lymphoma also account for almost half of all childhood cancers (age 0-14 years).
About the study
Dr. Veillette’s research was funded by the Canadian Institutes of Health Research, the Canadian Cancer Society Research Institute and the Canada Research Chairs program. The project was conducted at the IRCM by Luis-Alberto Pérez-Quintero (first author of the study), Romain Roncagalli, Huaijian Guo, Dominique Davidson and André Veillette, in collaboration with Sylvain Latour from the Institut des maladies génétiques Imagine in Paris.
For more information, please refer to the article summary published online by the Journal of Experimental Medicine.
About André Veillette
André Veillette obtained his medical degree from the Université Laval. He is Full IRCM Research Professor and Director of the Molecular Oncology research unit. Dr. Veillette is full research professor in the Department of Medicine (accreditation in molecular biology) at the Université de Montréal. He is also adjunct professor in the Department of Medicine (Division of Experimental Medicine) at McGill University. Dr. Veillette holds the Canada Research Chair in Immune System Signalling. For more information, visit www.ircm.qc.ca/veillette.
About the IRCM
Founded in 1967, the Institut de recherches cliniques de Montréal (www.ircm.qc.ca) is currently comprised of 35 research units in various fields, namely immunity and viral infections, cardiovascular and metabolic diseases, cancer and genetic diseases, neurobiology and development, systems biology and medicinal chemistry. It also houses four specialized research clinics (cholesterol, cystic fibrosis, diabetes and obesity, hypertension), eight core facilities and three research platforms with state-of-the-art equipment. The IRCM employs 425 people and is an independent institution affiliated with the Université de Montréal. The IRCM Clinic is associated to the Centre hospitalier de l’Université de Montréal (CHUM). The IRCM also maintains a long-standing association with McGill University. The IRCM is funded by the Quebec ministry of Higher Education, Research, Science and Technology.
– 30 –
Download the news release as a PDF document
For more information and to schedule an interview with Dr. Veillette, please contact:
Julie Langelier, Communications Officer (IRCM)
[email protected] | (514) 987-5555
Lucette Thériault, Communications Director (IRCM)
[email protected] | (514) 987-5535